Lantern Pharma is trading 5.67% down at $1.42, continuing the retreat from the September 21, 2026 close of $1.50, while the specific reason remains unclear.
- Lantern Pharma announced a USPTO Notice of Allowance for an LP-284 treatment patent covering several aggressive blood cancers.
- Expected protection extends through 2042.
- The announcement has not been identified as a catalyst, while biotechnology is broadly higher.